Ratings Camlin Fine Sciences Limited

Equities

CAMLINFINE

INE052I01032

Delayed Bombay S.E. 01:22:12 2024-06-07 am EDT 5-day change 1st Jan Change
96.67 INR +1.24% Intraday chart for Camlin Fine Sciences Limited +3.00% -28.84%

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Weaknesses

  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • The company does not generate enough profits, which is an alarming weak point.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Specialty Chemicals

1st Jan change Capi. Investor Rating ESG Refinitiv
-28.84% 192M -
+21.26% 68.69B
A-
-0.07% 49.19B
A-
+24.11% 44.73B
B+
+30.30% 28.24B
A-
+7.64% 19.22B
C+
+10.10% 16.68B
B+
-5.26% 16.08B
B+
-23.26% 15.62B
A-
-18.20% 13.89B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. CAMLINFINE Stock
  4. Ratings Camlin Fine Sciences Limited